WATERTOWN, MA & HARLEYSVILLE, PA — Hyperion Biosystems and Colorcon have announced a licensing agreement aimed at revolutionizing the fight against counterfeit pharmaceutical and nutraceutical products. The collaboration will bring a cutting-edge, on-dose authentication technology to market, enhancing the security and integrity of solid oral dosage forms.
This innovative solution integrates Hyperion Biosystems’ physics-based algorithms and AI-powered vision systems with Colorcon’s custom taggants. The result is a sophisticated anti-counterfeiting method that can be seamlessly incorporated into existing manufacturing processes, bolstering supply chain security while addressing FDA requirements for physical-chemical identifiers (PCID).
“This agreement is the result of a multi-year relationship between Hyperion Biosystems and Colorcon,” said Jason Cox, Ph.D., CEO of Hyperion Biosystems. “Our teams have closely collaborated to create a unique solution for on-dose authentication. By combining our expertise in authentication additives and our core Halo® product suite, we are supporting Colorcon’s efforts to solve the highly complex and growing challenge of counterfeit pharmaceutical and nutraceutical products in the global market.”
The technology is part of Colorcon’s SoteriaRx product line, which focuses on enhancing pharmaceutical security. “Colorcon is evaluating various ways to add on-dose authentication technology to its SoteriaRx product portfolio to meet the FDA requirements,” said Gary Pond, Director of Strategic Business Development at Colorcon. “This agreement with Hyperion Biosystems demonstrates our ongoing commitment to customers by offering innovative solutions that will improve security in the pharmaceutical supply chain, seamlessly integrating into existing manufacturing processes and most importantly, safeguarding both patients and trusted brands.”
Counterfeit medications pose a significant global threat, not only undermining public health but also eroding trust in trusted healthcare brands. The partnership between Hyperion Biosystems and Colorcon represents a significant step forward in addressing these challenges, leveraging advanced technology to enhance patient safety and ensure the authenticity of products worldwide.
By deploying this next-level authentication technology, the collaboration sets a new benchmark for pharmaceutical security, offering a proactive and highly effective measure against the increasing prevalence of counterfeit drugs in global markets.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.